Marco Meglio

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Thomas Crawford, MD. [LISTEN TIME: 24 minutes]

Pharmacokinetic results indicated that ACD856 has a suitable pharmacokinetic profile for further development with a rapid absorption, dose-dependent exposure, and a favorable metabolic profile.

The double-blind, placebo-controlled trial assesses change from baseline in the weekly average of daily self-reported worst pain intensity scores after 14 weeks of treatment.

Patients who continued on active treatment into the open-label extension saw continued improvements in their condition after 14 weeks.

Results showed that 67% of treated patients in Stage A demonstrated evidence of clinical improvement, indicating that IgG autoantibodies play a significant role in the underlying biology of CIDP.

In a large-scale, nationwide cohort, the impact of migraine on risk of premature myocardial infarction was slightly greater for women and may potentially only exist for women.

The executive vice president of the National MS Society provided insight on the Pathways to Cures roadmap, a global initiative to stop multiple sclerosis, restore function, and end MS.

In comparison with placebo, older adults on low-dose aspirin had an increase in a combination of subdural, extradural, and subarachnoid bleeding.

Concentrations of Aß42 and Aß40 were substantially higher in those with amyloid-ß-negative, tau-positive status compared with Aß-negative, tau-negative patients.

With the decision, ClarityPro becomes the first and only device to offer new technology add-on payment reimbursement for the diagnosis of electrographic status epilepticus.

The trial is expected to include 14 individuals with genetically confirmed limb-girdle muscular dystrophy who will be randomly assigned 1:1 to either AB-1003 or placebo for a year-long treatment period.

In the supporting phase 3 study, treatment with GA Depot resulted in statistically significant reductions in annualized relapse rate, the primary end point, and other secondary outcomes of T1 and T2 hyperintense lesions.

The time to osteoporosis was 23% faster with exposure to non-enzyme-inducing antiseizure medications and 9% faster for enzyme-inducing ASMs, independent of epilepsy.

Although treatment with tirofiban improved the odds of excellent outcome, results for the secondary end points did not consistently support the primary end point analysis.

After nearly 13 years of follow-up, 36% of patients with relapsing multiple sclerosis had a confirmed Expanded Disability Status Scale score worsening.

The combination of digital cognitive behavioral therapy and medication resulted in a sustained improvement in sleep quality compared with monotherapy modalities.

Because its gut-acting and gut-restricted, the safety profile of DGX-001 was considered advantageous in comparison to traditional neuropsychiatric therapies.

The pediatric neurologist at Johns Hopkins Medicine provided clarity on the recently published 5-year update of the NURTURE study, and the importance of treating spinal muscular atrophy at its presymptomatic stages.

Sleep stage percentages were not associated with global cognition across cohorts, while patients with mild to severe OSA displayed poorer global cognitive function.

Harmony aligned with the FDA on the proposed phase 3 design elements, which is expected to kick off later this year.

The findings provided safety and tolerability data for using liothyronine in future, larger studies of multiple sclerosis, with the potential to be observed in combination with other therapies.

Intravenous thrombolysis with recombinant human prourokinase resulted in a 16.4% lowered risk of systemic bleeding in comparison with alteplase treatment, which was consistent with previous phase 2 data.

With the new update, cladribine, glatiramer acetate, and rituximab, are now included in the Lists of Essential Medicines, filing a gap given the global burden of multiple sclerosis.

Andreas Muehler, MD, and Hella Kohlhof, PhD, provided answers on a recently published analysis showing considerable activation of nuclear receptor related 1 with vidofludimus calcium, an agent in development for various forms of multiple sclerosis.

The findings confirmed and expanded upon existing literature by demonstrating that the incidence rates of multiple cardiovascular events, including stroke, heart failure, and cardiovascular disease, are significantly higher in patients with narcolepsy.

Mind Moments®, a podcast from NeurologyLive®, brings you exclusive commentary from Alberto J. Espay, MD, PhD, and Anton P. Porsteinsson, MD. [LISTEN TIME: 48 minutes]

Completion of the 12-week program was associated with reported improvements in overall changes in sleep parameters of sleep latency, wake after sleep onset, sleep efficiency, and others.

The phase 1/2a studies are expected to be complete by the end of 2023, with data from the open-label extension studies to be shared in early 2024.

The director at the Foundation for the National Institutes of Health provided perspective on the effective ways to utilize currently available biomarkers for Alzheimer disease research.

In a patient case with tandem occlusion, treatment using the Zoom 88 Support resulted in reduced NIHSS score from 20 to 0.